Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjh.17823
PubMed Identifier: 34490623
Publication URI: http://europepmc.org/abstract/MED/34490623
Type: Journal Article/Review
Volume: 196
Parent Publication: British journal of haematology
Issue: 2
ISSN: 0007-1048